---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-114996"
form_type: "8-K"
ticker: "CYPH"
cik: "0001509745"
company_name: "CYPHERPUNK TECHNOLOGIES INC."
filed_at: "2022-11-07T23:59:59+00:00"
generated_at: "2026-06-22T05:19:06.458084+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Leap Therapeutics receives Nasdaq bid price deficiency letter; has until May 1, 2023 to regain compliance

## Summary
- Closing bid price below $1.00 for 30 consecutive business days triggered Nasdaq deficiency notice.
- Company has 180 days (until May 1, 2023) to regain compliance by closing at $1.00 for 10 consecutive days.
- If not compliant by May 1, may be eligible for an additional 180-day period subject to other listing standards.
- Failure to cure could result in delisting; company may appeal to Nasdaq Hearings Panel.

## SEC filing metadata
- accession: 0001104659-22-114996
- form_type: 8-K
- ticker: CYPH
- cik: 0001509745
- company_name: CYPHERPUNK TECHNOLOGIES INC.
- filed_at: 2022-11-07T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1509745/000110465922114996/0001104659-22-114996-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1509745/000110465922114996/tm2229684d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-114996
- JSON: https://secwatch.observer/filing/0001104659-22-114996.json
- Plain text: https://secwatch.observer/filing/0001104659-22-114996.txt

## Key facts
- Listing & Compliance Notices
  CYPHERPUNK TECHNOLOGIES INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5450(a)(1)
  source text: November 2, 2022, Leap Therapeutics, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the preceding 30 consecutive business days, the closing bid price for the Company’s common stock was below the minimum $1.00 per share requirement for continued inclusion on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). The notification received has no immediate effect on the Company’s Nasdaq listing. In accordance with Nas
  evidence_url: https://www.sec.gov/Archives/edgar/data/1509745/000110465922114996/0001104659-22-114996-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.